LipoScan: a mass spectrometry-based lipidomics platform for cancer diagnostics and target identification

Clinical disease management in an era of targeted and personalized medicine relies on effective targets and informative molecular biomarkers, particularly in the field of oncology where therapy options are rapidly expanding and responses are highly variable. Lipids take a special stage in this context. This class of molecules is dramatically affected in both cancer tissue and body fluids and substantially contributes to the etiology of the disease, creating unique opportunities for the development of biomarker tests and novel treatments. The LipoScan platform harnesses the power of mass spectrometry to simultaneously interrogate dozens of lipid species and to follow 13C-labeled tracers through lipid metabolism pathways, enabling the delineation of lipid-based biomarker signatures and therapeutic targets. Through a hybrid business model initiating from a service platform, a spin-off will be generated providing clinical diagnostic services and target development in the field of oncology.

Keywords:liposcan

Disciplines:Genetics, Systems biology, Molecular and cell biology